Vitality Watch

Dossier pubmed observational 01-aug-2026
Human cohort, case-control, or epidemiological association

Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study.

Key claim: In real-world practice, tirzepatide produced a mean 17.2% body-weight reduction at 6 months (median dose 7.5 mg), with most participants achieving ≥5% loss, cardiometabolic improvements, and favorable tolerability.

Abstract

BACKGROUND AND AIMS: Recent randomised controlled trials have demonstrated the efficacy of tirzepatide in inducing weight loss among adults with overweight or obesity, irrespective of diabetes mellitus status. However, evidence from real-world settings remains limited. This study aimed to evaluate the effectiveness and safety of tirzepatide for weight management in routine clinical practice. METHODS: This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/mor ≥27 kg/mand at least one weight-related comorbidity in real-world conditions. The primary outcomes were changes in body weight and body composition after 6 months of treatment. Secondary assessments included anthropometric and cardiometabolic parameters, quality of life, and tolerability. RESULTS: The median tirzepatide dose at 6 months was 7.5 mg. At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline. A total of 95.35% of participants achieved at least 5% weight loss, and 60.47% achieved ≥15%. Significant improvements were observed in glycaemic and lipid profiles, with enhancements in health-related quality of life and a favourable tolerability profile. The dropout rate was 3.7%. CONCLUSIONS: This prospective real-world study confirms the effectiveness and safety of tirzepatide for weight management, even at maintenance doses lower than the approved dose, and supports findings from randomised clinical trials.

Why this matters

In real-world practice, tirzepatide produced a mean 17.2% body-weight reduction at 6 months (median dose 7.5 mg), with most participants achieving ≥5% loss, cardiometabolic improvements, and favorable tolerability.

Source

Link

Briefing card

Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study.
Stage: observational · pubmed · 01-aug-2026

In real-world practice, tirzepatide produced a mean 17.2% body-weight reduction at 6 months (median dose 7.5 mg), with most participants achieving ≥5% loss, cardiometabolic improvements, and favorable tolerability.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.clnesp.2026.105005

build build 880 · 2bcef25 · 2026-11-18